Blueprint Medicines Corporation Stock News

CAMBRIDGE, Mass., Feb. 16, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2021. "Following a year of outstanding execution across our portfolio, we…

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -39.44% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines (NASDAQ:BPMC) is scheduled to announce Q4 earnings on Wednesday, Feb. 16, before market open.The consensus EPS estimate is -$1.57

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate

CAMBRIDGE, Mass., Feb. 11, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming investor conferences. SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 10:40 a.m. ET. Cowen 42nd…

CAMBRIDGE, Mass., Feb. 11, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming investor conferences.

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CAMBRIDGE, Mass., Feb. 9, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, February 16, 2022 to report its fourth quarter and full year 2021 financial results and provide…

Stocks, especially the once high flying technology stocks, had a lousy start to the new year. QQQ lost 9% of its value in January.

The European Medicines Agency''s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the use of Blueprint Medicines Corporation''s (NASDAQ: BPMC ) Ayvakyt (avapritinib). The positive opinion covers Ayvakyt as monotherapy for aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological … Full story available on Benzinga.com

Blueprint Medicines Corp (BPMC) shares closed 4.0% lower than its previous 52 week low, giving the company a market cap of $4B. The stock is currently down 23.9% year-to-date, down 24.0% over the past 12 months, and up 152.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 40.0% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 111.8% The company's stock price performance over the past 12 months beats the peer average by -52.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Blueprint Medicines <> shares have slumped after the company provided preliminary financial results for Q4 and full year 2021.The precision therapy company expects FY21

Blueprint Medicines' (BPMC) Ayvakit, approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. Other pipeline candidates are also progressing well

Blueprint Medicines' (BPMC) Ayvakit, approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. Other pipeline candidates are also progressing well

Torray LLC raised its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 34.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,938 shares of the biotechnology companys stock after purchasing an additional 4,089 shares during the quarter. Torray LLCs []